⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VRDN News
Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
businesswire.com
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
businesswire.com
VRDN
Viridian Announces Market Services Agreement With Outside The Box Capital
globenewswire.com
VRDN
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
globenewswire.com
VRDN
Form 8-K
sec.gov
VRDN
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
businesswire.com
VRDN
Form 8-K
sec.gov
VRDN
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
VRDN